English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Defective release of fibrinolytic activator from the. vessel walls implies an increased risk of thromboembolic disease (Isacson and Nilsson 1972). Therefore methods suitable for determination of the fibrinolytic “capacity” in man have become increasingly interesting. The fibrinolytic activity (FA) in blood after infusion of DDAVP (l-desamino-8-D-argininvasopressin) was determined in 21 normals and 42 patients with recurrent venous thrombosis. The results were compared with those found after venous occlusion (VO) in the same subjects. DDAVP induced a significant but lower increase of the fibrinolytic activity in blood than VO. The correlation was good between the FA immediately after DDAVP and VO both in normals (r = 0.53) and in patients (r = 0.63). Both DDAVP and VO induced a significantly lower FA in patients than in normals. All subjects studied showed an increase of the FA with both methods used. Both DDAVP and VO induced a significant increase of VIII:C and VIIIR:AG. This increase was about the same in the two groups. No side effects were found after infusion of DDAVP which thus seems to be suitable for determination of the fibrinolytic “capacity” in patients with thromboembolic disease.  Isacson, S. and Nilsson, I.M. 1972. Acta chir. scand. 138, 313.

Plasminogen Activator Release After Venous Occlusion and Infusion of DDAVP